307 related articles for article (PubMed ID: 21408027)
1. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
Bao B; Ali S; Kong D; Sarkar SH; Wang Z; Banerjee S; Aboukameel A; Padhye S; Philip PA; Sarkar FH
PLoS One; 2011 Mar; 6(3):e17850. PubMed ID: 21408027
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
[TBL] [Abstract][Full Text] [Related]
3. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
Bao B; Ahmad A; Kong D; Ali S; Azmi AS; Li Y; Banerjee S; Padhye S; Sarkar FH
PLoS One; 2012; 7(8):e43726. PubMed ID: 22952749
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment.
Bao B; Ali S; Ahmad A; Azmi AS; Li Y; Banerjee S; Kong D; Sethi S; Aboukameel A; Padhye SB; Sarkar FH
PLoS One; 2012; 7(12):e50165. PubMed ID: 23272057
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.
Bao B; Azmi AS; Aboukameel A; Ahmad A; Bolling-Fischer A; Sethi S; Ali S; Li Y; Kong D; Banerjee S; Back J; Sarkar FH
J Biol Chem; 2014 May; 289(21):14520-33. PubMed ID: 24719318
[TBL] [Abstract][Full Text] [Related]
7. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Kong D; Li Y; Ahmad A; Banerjee S; Azmi AS; Miele L; Sarkar FH
Cancer Lett; 2011 Aug; 307(1):26-36. PubMed ID: 21463919
[TBL] [Abstract][Full Text] [Related]
8. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH
Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
10. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
[TBL] [Abstract][Full Text] [Related]
11. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells.
Kanwar SS; Yu Y; Nautiyal J; Patel BB; Padhye S; Sarkar FH; Majumdar AP
Pharm Res; 2011 Apr; 28(4):827-38. PubMed ID: 21161336
[TBL] [Abstract][Full Text] [Related]
12. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
13. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling.
Ali S; Ahmad A; Aboukameel A; Ahmed A; Bao B; Banerjee S; Philip PA; Sarkar FH
Cancer Lett; 2014 Aug; 351(1):134-42. PubMed ID: 24839931
[TBL] [Abstract][Full Text] [Related]
15. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.
Roy S; Yu Y; Padhye SB; Sarkar FH; Majumdar AP
PLoS One; 2013; 8(7):e68543. PubMed ID: 23894315
[TBL] [Abstract][Full Text] [Related]
16. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.
Gu J; Wang D; Zhang J; Zhu Y; Li Y; Chen H; Shi M; Wang X; Shen B; Deng X; Zhan Q; Wei G; Peng C
Cancer Lett; 2016 Oct; 380(2):434-441. PubMed ID: 27400681
[TBL] [Abstract][Full Text] [Related]
17. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
18. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Hong SP; Wen J; Bang S; Park S; Song SY
Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
[TBL] [Abstract][Full Text] [Related]
19. MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin β1.
Yang D; Hu Z; Xu J; Tang Y; Wang Y; Cai Q; Zhu Z
Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31693728
[TBL] [Abstract][Full Text] [Related]
20. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
